 | ||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|||||||||||||||||||
| ||||||||||||||||||||
Please complete the following form to request a media kit.
|
|
Press Releases
We are committed to developing treatments to save lives and improve the quality of life of people suffering from these diseases worldwide. Today, our development efforts are centered on developing a treatment for HIV/AIDS based on our patented Thymus Nuclear Protein technology. Our first IBT candidate is VGV-1. Through five human trials outside the USA, promising data suggest our technology will have additional use beyond HIV/AIDS, including other infectious diseases, certain cancers, and autoimmune conditions.
|
||||||||||||||||||
|
Home | About Us | Our Team | Advisory Board | Discovery Our Vision | Immune-Based Therapies | TNP | Development | VGV-1 History | Product Timeline | Clinical Trials Press Releases | Media Kits | Media Inquiries | News Subscription Service Investor Contacts | Email Alerts | Contact Us | SEC Filings Glossary | Stock Information | Corporate Governance & Board of Directors University of Colorado License | Careers |
|
|||||||||||||||||||
 |
|
|||||||||||||||||||
